First we had fingolimod, then came siponimod, then oxazinimod and now we have ponesimod after the EMA approved it. These are all Sphingosine-1-phosphateone receptor modulators. Ponvory (ponesimod) is approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
“Relapsing multiple sclerosis is an unpredictable and complex disease that can present very differently from individual to individual, placing a heavy burden on the patient and their loved ones,” explained Professor Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Professor of Neurology at Queen Mary University of London, UK. “I welcome the European Commission’s approval of ponesimod as an additional treatment option for those living with relapsing multiple sclerosis – it will provide patients with additional choice when making decisions about their treatment.”
Markham A. Ponesimod: First Approval. Drugs. 2021 Jun;81(8):957-962. Ponesimod (PONVORY™) is an orally administered selective sphingosine-1-phosphate (S1P) receptor 1 (S1P1) agonist being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson for the treatment of multiple sclerosis (MS). Based on the results of the phase III OPTIMUM trial, ponesimod was recently approved in the USA for the treatment of relapsing forms of MS and has received a positive CHMP opinion in the EU for this indication.
The big question is how do you make the choice.
Fingolimod is indicated as single disease modifying therapy in highly active relapsing remitting multiple
sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:
- Patients with highly active disease despite a full and adequate course of treatment with at least
one disease modifying therapy
- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more
disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI
or a significant increase in T2 lesion load as compared to a previous recent MRI.
Ozanimod is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis
(RRMS) with active disease as defined by clinical or imaging features.
Siponimod is indicated for the treatment of adult patients with secondary progressive multiple sclerosis
(SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity